Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699809 | 0.78 | TRPV6 (0.57) | TRPV6SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL8323718 | 0.76 | MRGPRX4 (0.53) | KMT2APTGER1 | |
| SCHEMBL5699784 | 0.74 | ALDH1A1 (0.55) | TRPV6SMN1; SMN2ALDH1A1LMNATP53 | |
| SCHEMBL23434794 | 0.72 | MRGPRX4 (0.48) | PTGER1TDP1STAT3SLC6A4SLC6A3 | |
| SCHEMBL5699813 | 0.72 | L3MBTL1 (0.50) | TRPV6SMN1; SMN2LMNAKMT2AHTR2A | |
| SCHEMBL14775776 | 0.71 | PTGER1 (0.55) | SMN1; SMN2ALDH1A1LMNATP53KMT2A | |
| SCHEMBL25809489 | 0.71 | HTR2A (0.61) | SMN1; SMN2ALDH1A1LMNAHTR2ABCHE | |
| SCHEMBL23015299 | 0.70 | LOXL2 (0.59) | ALDH1A1LMNATP53KMT2AMEN1 | |
| SCHEMBL5700023 | 0.70 | CCR5 (0.65) | — | |
| SCHEMBL5700208 | 0.69 | CCR5 (0.55) | KMT2AKDM4EPTGER1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687268-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047249-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-26 | — | — | WO | claimed |
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | claimed |
| EP-1687268-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047249-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | CCR1, CCR3, CCR4 | TRPV6 824/4885SMN1; SMN2 2599/4885ALDH1A1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.